Increasing evidence suggests that metabolic impairments contribute to early Alzheimer’s disease (AD) mechanisms and subsequent dementia. Signals in metabolic pathways conserved across species can facilitate translation.
We investigated differences in serum and brain metabolites between the early-onset 5XFAD and late-onset LOAD1 (APOE4.Trem2*R47H) mouse models of AD to C57BL/6J controls at 6 months of age.
We identified sex differences for several classes of metabolites, such as glycerophospholipids, sphingolipids, and amino acids. Metabolic signatures were notably different between brain and serum in both mouse models. The 5XFAD mice exhibited stronger differences in brain metabolites, whereas LOAD1 mice showed more pronounced differences in serum.
Several of our findings were consistent with results in humans, showing glycerophospholipids reduction in serum of apolipoprotein E (apoE) ε4 carriers and replicating the serum metabolic imprint of the APOE ε4 genotype. Our work thus represents a significant step toward translating metabolic dysregulation from model organisms to human AD.

This was a metabolomic assessment of two mouse models relevant to Alzheimer’s disease.
Mouse models exhibit broad sex-specific metabolic differences, similar to human study cohorts.
The early-onset 5XFAD mouse model primarily alters brain metabolites while the late-onset LOAD1 model primarily changes serum metabolites.
Apolipoprotein E (apoE) ε4 mice recapitulate glycerophospolipid signatures of human APOE ε4 carriers in both brain and serum.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Ravi S. Pandey,
Mattias Arnold,
Richa Batra,
Jan Krumsiek,
Kevin P. Kotredes,
Dylan Garceau,
Harriet Williams,
Michael Sasner,
Gareth R. Howell,
Rima Kaddurah‐Daouk,
Gregory W. Carter | April 28, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents